Skip to main content

Intracavernosal Injection Agents

Intracavernosal injection (ICI) is an effective option for erectile dysfunction, including when oral therapy is unsuitable or ineffective. AUA does not require every patient to fail oral drugs first: discuss the suitable options and preferences. EAU 2026 recommends ICI as an alternative first-line treatment in well-informed patients or as second-line therapy (strong; level 1a evidence that alprostadil is effective, with high drop-out).[2] An in-office injection test and training should precede self-injection.[1][2]

Keep four uses distinct: vasoactive injections into the corpora for erections; diagnostic pharmacologic erection testing; intralesional plaque treatment for Peyronie's disease; and intracavernosal vasoconstrictor treatment to reverse a prolonged erection. Their drugs, sites and doses are not interchangeable.

Agents and formulations​

Agent / formulationRole and mechanismRegulatory / practical distinction
Alprostadil (PGE1): Caverject, EdexProstaglandin-mediated cAMP signaling relaxes cavernosal smooth muscleFDA-approved ED injection products. Caverject also has a diagnostic-adjunct indication; follow the individual product's dosing and preparation instructions.[3][4]
PapaverineNonspecific phosphodiesterase inhibitionED use is off-label; commonly combined with other agents. EAU 2026 gives 20–80 mg with response below 55% and calls it abandoned as monotherapy because of liver-enzyme elevation, priapism and fibrosis.[2]
PhentolamineNonselective alpha-receptor blockade reduces sympathetic contractionOff-label ED combination component; poor erectile response as monotherapy (EAU lists 0.5 mg/mL). It can cause systemic hypotension/reflex tachycardia, nasal congestion and gastrointestinal upset.[2]
BiMixPapaverine + phentolamineCompounded; may avoid alprostadil-associated pain, but response and risk vary. EAU 2026 text gives papaverine 7.5–45 mg with phentolamine 0.25–1.5 mg and about 90% response; its table lists 30 mg/mL with 0.5 mg/mL.[1][2]
TriMixAlprostadil + papaverine + phentolamineCompounded, with no single standard concentration. A 2025 systematic review found no consistent adverse-effect advantage for combined over single-agent ICI, with limited and heterogeneous comparative data.[13] EAU 2026 text gives papaverine 8–16 mg, phentolamine 0.2–0.4 mg and alprostadil 10–20 micrograms (its table lists 30 mg/mL, 1 mg/mL and 10 micrograms/mL), efficacy up to about 92%, less pain than alprostadil alone, and fibrosis in 5–10% depending on the papaverine dose.[1][2]
QuadMixTriMix + atropineLess established salvage combination; do not interpret the extra drug as proven greater efficacy or safety.[1]
Aviptadil + phentolamine (Invicorp)VIP-mediated cAMP activity plus alpha blockadeEAU's table calls it easily available but names no countries; authorization and supply vary by region and must be checked locally. It is not an FDA-approved US ED product. EAU 2026 describes 25 micrograms of vasoactive intestinal peptide with 1–2 mg phentolamine, response above 80% (including after other therapies failed), little pain and a negligible priapism risk.[2][6]

The Caverject label states that the safety and efficacy of combining it with other intracavernosal vasoactive drugs have not been established and that the risks of prolonged erection, priapism and hypotension may increase; the Edex label does not recommend such combinations. Compounded TriMix practice is therefore distinct from labeled monotherapy.[3][4]

Compounding. AUA notes that no combination product is FDA-approved, that pharmacies compound them to the prescriber's instructions, and that concentrations vary widely in the literature. Reported ratios are roughly papaverine 12–30 mg : alprostadil 10–20 micrograms : phentolamine 1 mg per mL. The AUA example of a standard regimen is 30 mg papaverine plus 10 micrograms alprostadil plus 1 mg phentolamine per mL, with a starting dose of 0.1–0.5 mL in the office. Alprostadil has limited shelf life in compounded preparations, and cost differs substantially between branded and compounded products.[1] AUA also describes a stepped 625-man program: papaverine plus phentolamine produced penetration-sufficient erections in 66.4% of all 625 men. Among the 210 who did not respond, 75 received alprostadil (36% response) and 135 received TriMix (72.6% response); 37 also received QuadMix (59.5% response), and 15 of the original 625 failed every protocol. Relative drug efficacy cannot be compared directly because the groups differed in ED severity.[1]

Alprostadil dosing: product-specific limits​

ProductInitial office dose: vasculogenic / psychogenic / mixed EDPure neurogenic ED, such as SCIUpper labeled dose boundary
Caverject2.5 micrograms1.25 microgramsDoses >60 micrograms not recommended
Edex2.5 micrograms1.25 microgramsStudied dose range 1–40 micrograms; doses >40 micrograms not studied

EAU 2026 describes alprostadil monotherapy as most effective at 5–40 micrograms (40 micrograms off label in some European countries), with the erection appearing after 5–15 minutes; this is a different framework from the US labels' low starting doses. These starting categories are from the labels; do not automatically classify every post-pelvic-surgery patient as pure SCI-type neurogenic ED. Aim for the lowest effective dose producing an intercourse-suitable erection lasting no more than about one hour.[3][4]

Caverject and Edex have different office titration/redosing instructions. Use the actual product label, not a merged schedule. The patient remains under observation until detumescence. Once a home dose is established, use no more than three injections per week, separated by at least 24 hours; do not repeat a dose at home for an inadequate response or combine treatments without the prescriber's plan.[3][4]

For a compounded mixture, the prescription and teaching sheet must specify every concentration, the volume and the corresponding syringe marking. A number of syringe “units” does not identify a drug dose across different mixtures. Re-titration may be needed when formulation or concentration changes. Follow the dispensing pharmacy's product-specific storage and beyond-use instructions.[1]

Training and follow-up​

Use the product's supplied or specified needle and preparation method. Caverject specifies a 29–30-gauge half-inch injection needle and dorsolateral injection in the proximal third of the penis. Avoid visible veins, the dorsal neurovascular structures and the ventral urethra; alternate sides/sites. Do not bend, straighten or reuse needles. The Caverject label reports retained needle fragments; instruct patients to contact the clinician promptly if a broken end cannot be seen or grasped.[3] Discard single-use material appropriately.[3][4]

Compress the injection site for five minutes or until bleeding stops. Anticoagulation increases local bleeding risk but is not a blanket reason to stop the anticoagulant; interruption requires a separate assessment of its indication and thrombotic risk. The Caverject label specifically advises compression for patients taking warfarin/heparin.[3]

Ensure the patient can demonstrate preparation, injection and sharps disposal, and has clear instructions for prolonged erection. Review tolerability, dose, penile examination and continued need; Caverject recommends reassessment approximately every three months. Injection-volume limits vary by product and concentration; 0.5 mL applies only where specified.[3][4]

Contraindications and important adverse effects​

The US Caverject label contraindicates use in men with hypersensitivity, penile implants or priapism-predisposing conditions such as sickle cell anemia/trait, leukemia or myeloma.[3] It contraindicates ED treatment in penile fibrotic/anatomic conditions including Peyronie's disease, angulation and cavernosal fibrosis.[3] Review the exact product and indication rather than assuming plaque injection and ED injection have identical restrictions.[3] EAU 2026 also lists bleeding disorders as a contraindication to intracavernosal alprostadil; the US labels separately warn of injection-site bleeding with anticoagulants.[2][3][4]

  • Pain: alprostadil-associated penile pain is common and may affect adherence; adjustment or a different formulation can be considered. EAU 2026 reports pain after about 11% of injections (in 50% of patients), prolonged erection 5%, priapism 1% and fibrosis 2% for alprostadil, and notes that sodium bicarbonate or local anesthetic can reduce pain and that tunical fibrosis may signal early Peyronie's disease and warrant stopping injections indefinitely.[2]
  • Fibrosis/curvature: document any baseline plaque, fibrosis or deformity before starting, then inspect periodically and evaluate new plaques or angulation. AUA found no clear agent-specific difference and no increase in reported fibrosis with longer follow-up, but its predominantly observational studies had variable adverse-event reporting and dropout that limit inference about cumulative risk.[1] EAU 2026 reports fibrosis in 5–10% when papaverine is used, depending on total dose.[2] The Caverject and Edex labels advise stopping treatment if angulation or cavernosal fibrosis develops; Edex reports penile fibrosis (including Peyronie's disease) in 7.8% over up to 24 months.[1][3][4]
  • Hypotension/bleeding: systemic exposure can be important; the Caverject label advises avoiding use with known cavernosal venous leakage. For ED treatment, Caverject and Edex generally should not be used when underlying cardiovascular status makes sexual activity inadvisable; assess fitness for sexual activity before prescribing.[3][4]
  • Prolonged erection: emergency instructions are necessary. Caverject trials reported 4% erections lasting 4–6 hours and 0.4% lasting >6 hours, using historical study definitions.[3] The Edex label's patient instruction uses six hours. Those definitions do not mean it is safe to wait six hours: AUA/SMSNA and the Caverject label set the threshold for seeking care at four hours.[3][4][7]
  • Rates by agent: in AUA's review, priapism was least frequent with alprostadil alone (mean 1.8%), although alprostadil alone had a mean 6.3% rate of prolonged or painful erections. Pain is highest with papaverine (on injection), alprostadil (with erection) and papaverine plus phentolamine. Selecting the appropriate dose and teaching dose titration are measures to minimize priapism risk.[1]
  • Anticoagulants: the Edex label cautions about concomitant heparin because intravenous alprostadil prolonged PTT and thrombin time in a pharmacodynamic study.[4]

Product-label safety details above apply to Caverject; compounded mixtures need their own assessment.[3]

Effectiveness and persistence with treatment​

Coombs 2012 included 1,412 men with complete data from a tertiary program. Among TriMix users, 89% reported intercourse-capable erections; priapism was recorded in 0.5% of the 1,412 men with complete study data.[5] Response was lower in diabetic and irradiated patients. By 36 months, 24% had stopped ICI for reasons other than a PDE5i response; discontinuation was higher after prostatectomy, but 52% of prostatectomy patients stopped because PDE5 inhibitors became effective.[5]

Al-Mitwalli 2025 reviewed 308 selected men switched to aviptadil/phentolamine after painful or ineffective alprostadil. At the three-month effectiveness assessment, 182/308 (59%) resumed penetrative activity; responses differed between pain-switchers and maximum-dose failures (76% versus 36%). One priapism event (0.3%) occurred. This retrospective cohort did not compare rescue formulations for safety or efficacy.[6]

Adherence depends on comfort, confidence, partner preferences, cost and recovery with other therapies. EAU 2026 cites drop-out of 41–68% for intracavernous pharmacotherapy, mostly within the first two to three months.[2] For intracavernous alprostadil, it reports satisfaction after injections of 87–93.5% in patients and 86–90.3% in partners.[2] A global review reported clinical efficacy in 54–100% of men and early discontinuation up to 38%, greatest in the first 3–6 months, with injection anxiety in about 65% that can persist for months.[11] In a single-center retrospective series of 105 long-term users (mean 8.4 years), self-rated rigidity rose from 41% to 90%; priapism (7.1%) and curvature under 30 degrees (10%) were reported.[11][12] Offer early follow-up after teaching rather than assuming that a good office erection predicts durable home use.[1][5]

Diagnostic ICI and penile Doppler​

Caverject's diagnostic label calls for an individual rigidity-producing dose using its vasculogenic/mixed titration framework, not a fixed 10–20-microgram starting dose for every patient. Specialist redosing protocols are distinct from home treatment instructions and require observation and a reversal plan.[3]

Incomplete relaxation, anxiety, dose response and measurement technique can affect Doppler interpretation. Redosing requires clinical assessment; a maximum dose may not produce complete relaxation. For hemodynamic thresholds, technique and interpretive limitations, use the dedicated penile Doppler page.[2]

Prolonged erection and priapism rescue​

Provide an explicit contact and emergency plan, and instruct every patient taught ICI (or given an in-office pharmacologic erection) to return to the office or emergency department for an erection lasting more than four hours .[7] AUA/SMSNA panel opinion: an erection under one hour after injection needs no intervention; one beyond four hours warrants treatment; between one and four hours, decide by rigidity (a partial erection unable to penetrate does not need treatment), whether rigidity is continuous, the agent and dose (TriMix and higher doses carry more risk than alprostadil alone), age and comorbidity. Pain is an unreliable guide because the injected drugs can themselves cause pain. Intracavernosal phenylephrine is the initial treatment when intervention is needed for a post-ICI erection of four hours or less ; it is also advised when conservative management fails .[7]

The AUA ED 2018 guideline describes commonly taught conservative measures, for which it found no evidence: attempting ejaculation, then oral pseudoephedrine, then an ice pack for 30–60 minutes; a painful, non-bendable erection that persists should go to the emergency room within 2–4 hours of injection.[1] AUA/SMSNA 2022 permits clinician-selected conservative measures for prolonged erections of 1–4 hours, while noting limited and inconsistent evidence. These measures must not delay definitive treatment of a fully rigid erection beyond four hours.[7]

For acute ischemic priapism, AUA/SMSNA recommends intracavernosal phenylephrine and corporal aspiration, with or without irrigation, before operative intervention .[14] Monitor blood pressure and heart rate during phenylephrine injection .[14] Use priapism management for preparation, dosing and escalation.[7][14]

Peyronie's plaque injections​

Collagenase and other intralesional agents are injected into a plaque, not prescribed as cavernosal erection drugs. See Peyronie's disease agents for selection, modeling, dosing and rupture precautions. Evidence from intralesional verapamil cannot be inferred from a trial of electromotive transdermal delivery.

After prostatectomy: assisted erections versus spontaneous recovery​

ICI can provide assisted erections while nerve-dependent responses are poor.[2] In a randomized trial of 30 preoperatively potent men after nerve-sparing retropubic prostatectomy, 8/12 men completing 12 weeks of thrice-weekly alprostadil injections reported spontaneous intercourse-sufficient erections at six months, compared with 3/15 assigned observation.[15]

Di Nauta and colleagues enrolled 397 of 570 eligible men in an observational rehabilitation program after open or robotic prostatectomy. In selected groups receiving PDE5 inhibitors plus VED, with or without ICI, the study reported up to 80% recovery at two years using IIEF-5 ≥21 with or without treatment aids; rehabilitation participants differed from nonparticipants in age and clinical characteristics.[8]

The Miranda randomized trial enrolled 76 men and had only 32 available across its three groups at 24 months. It found no significant final difference, but was too small/incomplete for a definitive negative conclusion. Cochrane's 2018 review mainly addressed scheduled PDE5 inhibitors, with very-low-certainty evidence and limited coverage of multimodal injection programs.[9][10]

See Also​

References​

1. Burnett AL, Nehra A, Breau RH, et al. Erectile Dysfunction: AUA Guideline. J Urol. 2018;200(3):633-641. doi:10.1016/j.juro.2018.05.004

2. EAU. Guidelines on Sexual and Reproductive Health, Limited Update March 2026, sections 5.6.7 (intracavernous injections; Table 5.5) and 5.6.12. Source.

3. CAVERJECT (alprostadil). US prescribing information. Source.

4. EDEX (alprostadil). US prescribing information. Source.

5. Coombs PG, Heck M, Guhring P, et al. A review of outcomes of an intracavernosal injection therapy programme. BJU Int. 2012;110(11):1787-91. doi:10.1111/j.1464-410X.2012.11080.x

6. Al-Mitwalli A, Holden F, Di Giovanni A, et al. Intracavernosal injection of aviptadil and phentolamine for refractory erectile dysfunction. J Sex Med. 2025;22(5):726-730. doi:10.1093/jsxmed/qdaf067

7. Bivalacqua TJ, Allen BK, Brock GB, et al. The Diagnosis and Management of Recurrent Ischemic Priapism, Priapism in Sickle Cell Patients, and Non-Ischemic Priapism: An AUA/SMSNA Guideline. J Urol. 2022;208(1):43-52. doi:10.1097/JU.0000000000002767. The Diagnosis and Management of Priapism: an AUA/SMSNA Guideline (2022), unified full guideline.

8. Nauta MD, Falagario UG, Ricapito A, et al. Sexual function recovery following open and robotic radical prostatectomy: results of an academic penile rehabilitation program. Asian J Androl. 2025;27(6):680-685. doi:10.4103/aja202525

9. Miranda EP, Benfante N, Kunzel B, et al. A randomized, controlled, 3-arm trial of pharmacological penile rehabilitation in the preservation of erectile function after radical prostatectomy. J Sex Med. 2021;18(2):423-429. doi:10.1016/j.jsxm.2020.10.022

10. Philippou YA, et al. Penile rehabilitation for postprostatectomy erectile dysfunction. Cochrane Database Syst Rev. 2018;CD012414. Source.

11. Duncan C, Omran GJ, Teh J, et al. Erectile dysfunction: a global review of intracavernosal injectables. World J Urol. 2019;37(6):1007-1014. doi:10.1007/s00345-019-02727-5

12. Bearelly P, Phillips EA, Pan S, et al. Long-term intracavernosal injection therapy: treatment efficacy and patient satisfaction. Int J Impot Res. 2020;32(3):345-351. doi:10.1038/s41443-019-0186-z

13. Lima AS, Villela BC, Pustilnik HN, et al. "Comparison of adverse effects of combined and isolated substances in Intracavernosal injection: a systematic review and meta-analysis." J Sex Med. 2025;22(9):1579-1591. doi:10.1093/jsxmed/qdaf172

14. Bivalacqua TJ, Allen BK, Brock G, et al. "Acute Ischemic Priapism: An AUA/SMSNA Guideline." J Urol. 2021;206(5):1114-1121. doi:10.1097/JU.0000000000002236

15. Montorsi F, Guazzoni G, Strambi LF, et al. "Recovery of spontaneous erectile function after nerve-sparing radical retropubic prostatectomy with and without early intracavernous injections of alprostadil: results of a prospective, randomized trial." J Urol. 1997;158(4):1408-1410. doi:10.1016/S0022-5347(01)64227-7